Cardiovascular Risk in Cutaneous Lupus Erythematosus
A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients.
News
Lung Involvement in Still's Disease
A multicentre registry observational study assessed lung involvement in a cohort of Still’s disease patients, affirming pleuritis as most common and that parenchymal lung inflammatory disease is very uncommon in both children and adults.
ACR: Congress Fails to Reform PBMs, Mitigate Medicare Cuts
ACR
The American College of Rheumatology (ACR) commended the limited extension of key Medicare telehealth coverage provisions but also expressed disappointment that Members of Congress have failed to pass measures to bring transparency to pharmacy benefit manager (PBM) practices, address flawed insur
Fallen Angels (1.17.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.
Childhood Maltreatment and the Risk of Rheumatic Diseases
EurekAlert!
A UK retrospective matched open cohort study shows that children who suffered frmo abuse, neglect or domestic abuse carry a significantly increased risk of developing rheumatoid arthritis or psoriasis in later life.
Outcomes of Multisystem Inflammatory Syndrome in Children (MIS-C)
A nationwide cohort study of patients with multisystem inflammatory syndrome in children (MIS-C), a life-threatening complication of COVID-19 infection, showed that many had severe disease during the acute phase, but most recovered quickly and had a reassuring midterm prognosis.
Screening for Osteoporosis to Prevent Fractures - USPSTF Recommendations
The US Preventive Services Task Force (USPSTF) has done a systematic review on osteoporosis screening to prevent fractures and put forth its recent recommendations.
BACHELOR Trial - Baricitinib in Early Polymyalgia Rheumatica
Lancet reports a French study demonstrating the efficacy of baricitinib in patients with polymyalgia rheumatica (PMR).
2024 In Memorium
Sadly, in 2024, Rheumatology lost many of our greatest brethren, mentors, do-gooders and clinicians. These clinicians were responsible for the care of hundreds of thousands with MSK problems, while driving the scientific advances that will shape the lives of millions in the future. They did the painstakingly hard work of caring for the most complex patients and did so with zeal, wonder and love for their patients. Remember them, honor them, and invoke their names and memories frequently as they are the foundation upon which we rheumatologists stand.
Dazukibart Effective in Adults with Dermatomyositis
Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).
Eltrombopag, a Potential New Treatment for ITP
A pilot trial has shown a thrombopoietin receptor agonist, eltrombopag (Promacta), to be effective in connective tissue disease-related (CTD), refractory immune thrombocytopenia (ITP).
Alive in 2025 (1.10.2025)
Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com